Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers

Prentoe, Jannick; Janitzek, Christoph M.; Velázquez-Moctezuma, Rodrigo; Soerensen, Andreas; Jørgensen, Thomas; Clemmensen, Stine; Soroka, Vladislav; Thrane, Susan; Theander, Thor; Nielsen, Morten A.; Salanti, Ali; Bukh, Jens; Sander, Adam F.

Published in:
npj Vaccines

DOI:
10.1038/s41541-022-00570-1

Publication date:
2022

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Prentoe, J., Janitzek, C. M., Velázquez-Moctezuma, R., Soerensen, A., Jørgensen, T., Clemmensen, S., Soroka, V., Thrane, S., Theander, T., Nielsen, M. A., Salanti, A., Bukh, J., & Sander, A. F. (2022). Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers. npj Vaccines, 7, [148]. https://doi.org/10.1038/s41541-022-00570-1
Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers

Jannick Prentoe, Christoph M. Janitzek, Rodrigo Velázquez-Moctezuma, Andreas Soerensen, Thomas Jørgensen, Stine Clemmensen, Vladislav Soroka, Susan Thrané, Thor Theander, Morten A. Nielsen, Ali Salanti, Jens Bukh, and Adam F. Sander

Development of B-cell-based hepatitis C virus (HCV) vaccines that induce broadly neutralizing antibodies (bNAbs) is hindered by extensive sequence diversity and low immunogenicity of envelope glycoprotein vaccine candidates, most notably soluble E2 (sE2). To overcome this, we employed two-component approaches using self-assembling virus-like particles (cVLPs; component 1), displaying monomeric or oligomeric forms of HCV sE2 (sE2mono or sE2oligo; component 2). Immunization studies were performed in BALB/c mice and the neutralizing capacity of vaccine-induced antibodies was tested in cultured-virus-neutralizations, using HCV of genotypes 1–6. sE2-cVLP vaccines induced significantly higher levels of NAbS ($p = 0.0065$) compared to corresponding sE2 vaccines. Additionally, sE2oligo-cVLP was superior to sE2mono-cVLP in inducing bNAbs. Interestingly, human monoclonal antibody AR2A had reduced binding in ELISA to sE2oligo-cVLP compared with sE2mono-cVLP and competition ELISA using mouse sera from vaccinated animals indicated that sE2oligo-cVLP induced significantly less non-bNAbs AR2A ($p = 0.0043$) and AR1B ($p = 0.017$). Thus, cVLP-displayed oligomeric sE2 shows promise as an HCV vaccine candidate.

npj Vaccines (2022) 7:148; https://doi.org/10.1038/s41541-022-00570-1

INTRODUCTION

Hepatitis C virus (HCV) is a highly diverse virus with six clinically relevant genotypes and large variation in geographic distribution. Globally, more than 1 million people die every year from chronic-HCV-related disease and while effective drugs targeting virus functions are now available, the disease burden is still increasing globally due to frequent undiagnosed infection, high drug cost, and poor healthcare infrastructure in developing countries. Due to these challenges, the World Health Organization (WHO) explicitly urges research into developing HCV vaccines. The relevance of basing HCV vaccines on E2 was further supported by our recent finding that it was challenging for HCV to evade antibodies targeting the E2 antigenic region 3 (AR3). Another E2 epitope of vaccine interest is the linear E2 epitope termed, antigenic site 4 (AS412), which, in the absence of interfering antibodies against another part of E2, also shows potential as a vaccine target. In addition, it was recently found that AS412 could induce NAbS when stabilized either on hepatitis B surface antigen or displayed as a peptide mimic on anti-idiotypic antibodies. However, an inherent problem is the induction of antibodies against poorly conserved epitopes, such as antigenic region 1 (AR1), as well as against epitopes that are highly cryptic in the context of virus particles, such as antigenic region 2 (AR2).

While many research groups have contributed ways to improve immunogenicity of sE2, it remains challenging to produce HCV vaccine antigens that are both immunogenic and adaptable to proven vaccine modalities. In the attempt to overcome this barrier, sE2 has been genetically fused to different proteins, which can self-assemble into nanoparticles (NP) displaying multiple copies of monomeric sE2. This offers a way to boost the immunogenicity of sE2, by allowing the antigen to be delivered in a multivalent and highly repetitive format. However, it is currently unclear whether bNAb epitope display is best achieved using monomeric or oligomeric forms of sE2. Indeed, aggregate forms of sE2 have been shown to induce higher levels of bNAbs, which could reflect that bNAb epitopes are relatively more...
RESULTS

sE2-cVLP HCV vaccine generation and characterization

To develop E2-based cVLP vaccines against HCV, the sE2 antigen (Con1 isolate; genotype 1b) was genetically fused at the C-terminus to SpyTag (Fig. 1A) and was subsequently expressed in Drosophila Schneider 2 (S2) insect cells. The SpyTag can spontaneously form a covalent bond with the SpyCatcher protein on the surface of pre-assembled cVPs (Fig. 1B). Mono- and oligomeric states of the recombinant HCV sE2 were obtained following purification by ion metal affinity chromatography (IMAC) and size separation using size exclusion chromatography (SEC). From the SEC purification it was evident that the IMAC purified protein segregated into three peak fractions (Fig. 1C). Subsequent SDS-PAGE analysis of the SEC fractions indicated that peak 3 contained impurities and high-order oligomeric forms of sE2, whereas the majority of peak 1 and 2 contained the sE2 protein at different oligomeric states (Fig. 1C). Further analytical SEC of purified sE2 against marker proteins of known size, supported that peak 1 represented sE2 monomer (Fig. 1E), whereas the disulfide-mediated sE2 dimers, observed by non-reduced SDS-PAGE (Fig. 1D, peak 2; without DTT), might represent tetramers (referred to as oligomers from this point) in solution (Fig. 1E). Based on these results, both monomeric and oligomeric sE2 were further tested as vaccine antigens.

Monomeric and oligomeric sE2 (with C-terminal SpyTags) were mixed with AP205 cVPs (each displaying 180 SpyCatcher binding partners), which allowed the HCV sE2 antigens to be directionally attached at high density to the surface of cVPs (Fig. 1B; SDS-PAGE of the reactions shown for monomeric sE2 in Fig. 1F). Centrifugation of the resulting sE2-cVLP complexes (at 16,000 RCF for two minutes) did not cause precipitation for either monomeric or oligomeric sE2, demonstrating that the vaccines were soluble and stable (Fig. 1F, comparing intensity of CLP-E2 band in lane 3 to lane 2; Fig. 1G, comparing intensity of CLP-E2 band in lanes 4 to 3). Transmission electron microscopy (TEM) imaging showed the presence of monodisperse cVPs of ~40 nm in diameter for monomeric sE2 (Fig. 1H) and oligomeric sE2 (Fig. 1I), confirming that the cVPs had formed successfully. These results were supported by dynamic light scattering (DLS) measurement, showing a single population of cVPs with ~50 nm in diameter and percent polydispersity (%Pd) of 22.6 and 14.6% for monomeric and oligomeric sE2-cVLP vaccines, respectively.

Coupling HCV sE2 to cVPs increases the induction of NAb in immunized mice

Mice were immunized using a prime-boost-boost regimen with either monomeric or oligomeric HCV sE2 antigens, alone or displayed on the surface of the cVPs, as described above. Animals were euthanized at three weeks after the final booster immunization (week 9) and IgG was purified and used for in vitro testing of binding and neutralization (Fig. 2A). To assess the immunogenicity of vaccines containing monomeric and oligomeric sE2, respectively, sE2-specific antibody titers were measured by ELISA. Specifically, monomeric sE2 was used for capture of anti-E2 IgG induced by cVPs displaying monomeric sE2. Similarly, oligomeric sE2 was used for capture of anti-E2 IgG induced by cVPs displaying oligomeric sE2. cVPs displaying monomeric sE2 antigen produced significantly higher antibody titers (p = 0.03, geometric mean of reciprocal of 50% max optical density titer measured at 17.998) compared to the non-displayed sE2 antigen (geometric mean of titer 3.526, Fig. 2B) used for benchmarking. For oligomeric sE2 the trend was similar, but the antibody titers induced by the oligomeric sE2-cVP vaccine (geometric mean of titer 3.500) were not statistically significantly different to those induced by the non-displayed, oligomeric sE2 antigen (geometric mean of titer 1.700, Fig. 2C). To directly compare the level of sE2-specific antibodies induced by cVPs displaying monomeric and oligomeric sE2, respectively, serum samples taken three weeks after the 1st booster immunization (week 6) were analyzed in the same ELISA, using either monomeric or oligomeric sE2 as capture antigen. Here, we observed no difference in the ELISA titers (Supplementary Fig. 1A, B).

To measure the vaccine-relevant functionality of the induced IgG following immunization with monomeric/oligomeric sE2-cVP HCV vaccines or non-displayed controls, HCV neutralization assays were conducted using the genotype-matched HCVcc, J4 (genotype 1b). Virus stocks were generated, and the envelope protein sequences confirmed as previously described17. Focus forming unit (FFU) reduction assays were performed by pre-incubating a dilution series of total IgG purified from immunized mouse serum with J4 HCVcc recombinant virus, prior to infection of HCV-permissive HuH7.5 cells. Specifically, when the sE2 antigens (monomeric and oligomeric) were displayed on cVPs we observed neutralization in 5 out of 6 animals, as compared with 1 out of 6 animals for the non-cVP-displayed sE2 antigens. While statistical significance for the benefit of displaying sE2 on cVPs was not reached for monomeric (p = 0.1) or for oligomeric sE2 (p = 0.11) when analyzed alone (Fig. 2D, E), the benefit was highly significant when the cVP-coupled samples were pooled and compared to non-displayed samples (p = 0.0065; Fig. 2F). Intriguingly we also observed a trend for increased induction of NAb
using cVLP-coupled oligomeric sE2 compared with cVLP-coupled monomeric sE2.

Oligomeric HCV sE2 displayed on cVLPs induces cross-genotype-reactive bNAbs

To further test whether cVLP-displayed oligomeric sE2 induced higher levels of bNAbs than cVLP-displayed monomeric sE2, we performed dose-response FFU reduction assays against HCVcc of isolates TN (genotype 1a) and J6 (genotype 2a). Here, we observed that oligomeric sE2 induced significantly higher TN neutralizing titers ($p = 0.04$), as well as increased neutralization of J6, which was close to being statistically significant ($p = 0.06$) (Fig. 3A, B). J6 was generally much less neutralized than TN, which could be due to either epitope differences between the antigen isolate (Con1; genotype 1b) and J6 (genotype 2a) or be due to the fact that J6 is generally a hard-to-neutralize strain.\(^\text{19,40}\). For J6, only cVLP-displayed oligomeric sE2 induced any quantifiable neutralization. Thus, these data indicated that cVLP-coupled oligomeric sE2 was a superior HCV vaccine antigen.

Fig. 1 Development of cVLPs populated with monomeric or oligomeric HCV sE2. A A schematic illustrating the soluble Con1 (genotype 1b) E2 (sE2) construct used in this study with deletion of part of the stem and the entire transmembrane region (TM) and a C-terminal tag consisting of a 6x polyhistidine (HIS) tag followed by a SpyTag (ST). HVR1 and HVR2, hypervariable region 1 and 2. VR3, variable region 3. B A schematic illustrating the principle of the two-component tag/catcher cVLP used to make HCV sE2-cVLPs. C Following IMAC purification of sE2 (see Materials and Methods) the protein was further purified using SEC, where it eluted in three distinct peaks. D These peaks were evaluated in SDS-PAGE by Coomassie staining either with or without reducing agent (DTT). E Peaks 1, 2, and 3 were further evaluated using analytical SEC against proteins of known size. F SDS-PAGE gel showing the AP205 CLP prior to monomeric sE2 antigen coupling (Lane 1), Lanes 2 and 3 show the sE2-cVLP vaccine mixture (after 36 h incubation) before (Lane 2) and after (Lane 3) centrifugation ($16,000 \times g$ for 2 min). Lane 4 shows the final sE2-CLP after removal of excess sE2 antigen by ultracentrifugation. G SDS-PAGE gel showing oligomeric sE2 antigen input (Lane 1), the uncoupled AP205 cVLP (Lane 2). Lanes 3 and 4 show the sE2-cVLP vaccine mixture (after 36 h incubation) before (Lane 3) and after (Lane 4) centrifugation ($16,000 \times g$ for 2 min). Lane 5 shows the final sE2-CLP product after removal of excess sE2 antigen by ultracentrifugation. Densitometric analysis estimates both coupling efficiencies at ~60% (ImageQuantTL). H TEM image of monomeric sE2 coupled to cVLPs. Images were taken using similar EM settings and the scalebar represents 200 nm. All the lanes within each gel included in Fig. 1 was processed at the same time.
A schematic illustrating the immunization schedule and serum collection from BALB/c mice. Dose-response ELISAs against either monomeric (B) or oligomeric (C) sE2 of week 9 mouse serum samples collected from animals immunized either with (B) monomeric or (C) oligomeric sE2 alone or cVLPs. ELISAs were done in single replicates using anti-mouse IgG coupled to HRP and subsequently a colorimetric TMB substrate signal was detected. Binding results were assessed by four parameter curve fitting to calculate OD\textsubscript{50} values. Data is represented with median value of inverse OD\textsubscript{50} values of purified IgG from individual animals. D, E Dose-response neutralization of HCV recombinant J4 (genotype 1b) HCCVc was done in three replicates using mouse IgG and was evaluated in FFU reduction assays on Huh7.5 cells. Following 48 h of infection the cells were fixed and FFUs were visualized using HCV anti-nSSA antibody followed by anti-mouse antibody coupled to HRP followed by DAB staining of FFUs. Results were normalized to non-infected control cells and neutralization was assessed by four parameter curve fitting to calculate IC\textsubscript{50} values. If 50% neutralization was not reached at the highest tested dose then IC\textsubscript{50} values were interpolated if neutralization at highest dose reached a minimum of 30% and increased to at least 50% at 3 mg/ml. Data is represented with median value of inverse IC\textsubscript{50} values of purified IgG from individual animals. F The IC\textsubscript{50} values from panels D and E were pooled into groups where antigen was either coupled to VLPs or not. Statistical significance testing was done using non-parametric Mann-Whitney tests (Graphpad Prism 9.2.0) and the significance threshold was set at 95%.

To further test the capacity of oligomeric sE2 coupled to cVLPs to induce bNAbs in mice, we performed additional HCCVc neutralization experiments. However, due to limited sample availability we were unable to perform dose-response neutralization experiments and instead performed single moderate dose IC\textsubscript{50} neutralization at 0.4 mg/ml against a panel of viruses representing HCV genotypes 1–6; H77 (genotype 1a), T9 (2a), DBN (3a), ED43 (4a), SA13 (5a) and HK6a (6a). IgG from the majority of animals immunized with cVLP-displayed oligomeric sE2 contained bNAbs against H77, DBN, ED43, and SA13 (Fig. 3C, E–G). The low effect against the genotype 2a virus, T9, at 0.4 mg/ml IgG, was not unexpected (Fig. 3D), as we observed a mean IC\textsubscript{50} value at or greater than 1.8 mg/ml for the genotype 2a virus, J6 (Fig. 3B). Also, although the genotype 6a isolate, HK6a, is very sensitive to NABs\textsuperscript{38}, we did not observe convincing neutralization, indicating that perhaps this antigen does not induce effective NABs against genotype 6 (Fig. 3H). Overall, we concluded that cVLP-displayed oligomeric sE2 was capable of inducing robust bNAb responses against the majority of tested strains.

cVLPs displaying monomeric and oligomeric sE2 exhibit different antigenicity and induce anti-E2 IgG responses with different specificity

To investigate antigenic differences between monomeric and oligomeric sE2 displayed on cVLPs, titration series of human monoclonal NABs AR1B, AR2A, and AR3A were tested for binding to immobilized sE2-cVLP complexes (either monomeric or oligomeric sE2) in ELISA. This showed that the monoclonal NABs, which target the AR1B and the cross-genotype conserved AR3A epitope, respectively, bind similarly to cVLPs displaying monomeric or oligomeric sE2 (Fig. 4A, B). However, the monoclonal NAB, targeting the AR2A epitope (known to be poorly accessible on HCV virus particles), showed decreased binding to cVLP-coupled oligomeric sE2 (Fig. 4A, B).

We next performed competition ELISAs using serum drawn at three weeks after the 1st booster immunization (week 6) with either monomeric or oligomeric sE2 coupled to cVLPs. Here, we observed dose-response inhibition of binding for the three tested antibodies: AR1B, AR2A, and AR3A (Supplementary Fig. 2A–I). In addition, statistical analysis at the highest tested dose revealed similar levels of AR3A antibodies, but significant reduction in the induction of AR2A (p = 0.0043) and AR1B (p = 0.017) antibodies by oligomeric sE2 coupled to cVLPs (Fig. 4C–E). Taken together, this suggests that oligomeric sE2 coupled to cVLPs has an altered, and likely advantageous, antigenic profile compared with monomeric sE2 coupled to cVLPs.

DISCUSSION

Combating the continued spread of HCV hinges on developing a vaccine that prevents chronicity. Here, we employ a two-component vaccine platform based on cVLPs to deliver monomeric and oligomeric HCV sE2, respectively. Head-to-head comparison of vaccine formulations (all including Addavax adjuvant) showed that cVLP display had no significant effect on the overall immunogenicity of the sE2 antigen. However, mice that were immunized with cVLP-displayed sE2 induced anti-E2 IgG with an improved capacity for neutralizing HCV in vitro. Furthermore, this effect was greater for cVLPs displaying oligomeric sE2 than for cVLPs displaying monomeric sE2, indicating that cVLP-display of oligomeric E2 assemblies may represent a superior HCV vaccine design. This superiority may be linked to an altered antigen profile of cVLPs displaying sE2 oligomers. In support of this hypothesis, our data indicate that AR2A-specific epitopes are less exposed on cVLPs displaying oligomeric sE2 and that these appear to induce less AR2A- and AR1B-specific antibodies compared to cVLP displaying monomeric sE2.

We show proof-of-concept that displaying sE2 on cVLPs boosts the induction of HCV bNAbs, which is in agreement with the findings of others using single-component VLP/NP approaches for HCV (i.e., where the antigen is genetically fused to the particle-forming
Importantly, the two-component (i.e., modular) nature of the employed cVLP vaccine design permits the comparison of monomeric and multimeric antigens. Modifications of HCV sE2 can increase the ability of the protein to induce bNAbRs\textsuperscript{26–31} and studies have shown that some E2 antigen designs (E2 receptor-binding domain lacking three variable regions) can form disulfide-linked high-molecular-weight (HMW) E2 proteins that, when used as vaccine antigens, elicit antibodies with an increased neutralizing activity compared with corresponding monomeric species\textsuperscript{26,29,41}. Interestingly, the increased ability of these HMW E2 antigens for
generating bNAbs was shown to be correlated with occlusion of the non-neutralizing face of E2 in the oligomeric assembly state. Here, we identify an SEC fraction containing oligomeric sE2 which, in non-reducing SDS-PAGE, migrates as a sE2 dimer and that according to analytical SEC has the size of a sE2 tetramer. This enabled a direct comparison of the antigenic properties of oligomeric versus monomeric sE2 delivered by the same cVLP vaccine platform. Interestingly, we found that oligomeric sE2 induced cross-genotype reactive bNAbs capable of neutralizing all epidemiologically relevant genotypes, with the possible exception of genotype 6a, although an effect might have been observed at higher IgG concentrations. In comparison, cVLPs displaying monomeric sE2 induced inferior NAb responses. Antigenic characterization revealed that the AR2A epitope, which is known to be neutralizing, but poorly accessible on infectious virus particles\textsuperscript{24,25}, was less antigenic on oligomeric sE2 displayed on cVLPs, compared with monomeric sE2 on cVLPs. This difference may be linked to the results obtained by competition ELISAs, showing that animals immunized with oligomeric sE2 coupled to cVLPs have less antibodies competing with the human monoclonal anti-AR2A and AR1B antibodies. Collectively, these data underline antigenic differences between monomeric and oligomeric sE2, which may be directly involved in the improved induction of bNAbs by oligomeric sE2 on cVLPs.

Thus, our data suggests that cVLP display of oligomeric sE2 represents a promising design for an HCV vaccine. Future studies should clarify whether additional E2 antigens, based on sequences from other HCV isolates, will exhibit similar qualitative differences when delivered in monomeric and oligomeric forms, respectively.
Also, optimization of the gene design and subsequent protein purification procedures could lead to further antigen improvements and is needed to enable large-scale antigen production. Furthermore, future HCV vaccine studies could benefit from recently developed HCV pseudo-particle or HCVcc virus panels, representing much of the diversity in HCV neutralization sensitivity\textsuperscript{46,47}, which will provide a platform for comparing the vaccine potential across different approaches developed in different labs.

Thus, we show proof-of-concept that the two-component cVLP-based vaccine platform boosts the induction of HCV bNAb. Importantly, the two-component approach permitted testing oligomeric sE2-cVLPs, which showed the induction of statistically significant higher levels of bNAb, compared with monomeric sE2-cVLPs. This is of particular interest as we and others have shown how sE2 or detergent-extracted E1E2 protein only partly recapitulates the behavior of virion-associated E1/E2 complexes\textsuperscript{43–47}. Thus, our findings suggest that future complex HCV envelope antigens, such as iterations of the recently described native-like sE1E2 antigens\textsuperscript{15} or the sE1E2 permutated antigens\textsuperscript{48}, could benefit from being combined with the cVLP approach described here, or similar two-component VLP platforms, to boost bNAb responses in animals and humans.

In summary, by decorating cVLPs with oligomeric HCV sE2 protein we are able to greatly boost the induction of bNAb. These data offer important insights to be used for the design of a protective HCV vaccine.

**METHODS**

**Recombinant antigen expression**

Production of soluble, recombinant E2 (sE2) antigen was based on the Con1 (genotype 1b) isolate sequence (amino acids 384–661)\textsuperscript{35,49}, which was truncated in the C-terminal transmembrane stem region. The gene sequence was modified to contain an N-terminal BiP sequence as well as a C-terminal 6x polyhistidine (HIS) tag followed by a SpyTag (Fig. 1A). The final gene had flanking restriction sites (EcoRI and NotI) added to the N- and C-terminus and was codon optimized for expression in *Drosophila* Schneider 2 (S2) insect cells. The gene was synthesized by GeneArt (Thermo Scientific) and subcloned into the pExpress\textsuperscript{5}-1 (zeocin resistance) vector (Express\textsuperscript{5}ion Biotechnologies, Horsholm, Denmark) using EcoRI and NotI restriction sites.

The S2 cell culture supernatant was concentrated five times and buffer exchanged into 20 mM Tris, 0.5 M NaCl, pH 7.9 using a tangential flow filtration system (Quixstand Benchtop system, MWCO 10 kDa). Concentrated and buffer exchanged supernatant was loaded onto 5 ml HisTrap\textsuperscript{TM} HP columns for ion metal affinity chromatography (IMAC) and purified using the above buffer with 60 mM Imidazole and increasing to 0.5 M Imidazole in the elution buffer for step elution of the bound protein. The elution peak was further purified by size exclusion chromatography (SEC) on a 200 pg Sephadex column. Post purification SEC fractions of peak 1 and 2 (Fig. 1C) were used for subsequent immunization studies as monomeric and oligomeric sE2 antigens, respectively.

**AP205 cVLP production**

The SpyCatcher-AP205 cVLP is assembled from fusion proteins comprising the major capsid protein of the Acinetobacter phage AP205 (Gene ID: 956335) and SpyCatcher (Genbank: AFDS637, aa 24-139), respectively. Specifically, the SpyCatcher-AP205 sequence was constructed by fusing the SpyCatcher sequence to N-terminus of the AP205 coat protein, using a flexible linker (Gly-Gly-Ser-Gly-Ser), and subsequently adding flanking Ncol and NotI restriction sites at the N- and C-termini, respectively. The gene sequence was finally codon-optimized for recombinant expression in *E. coli* and synthesized by (GeneArt\textsuperscript{®} Life Technologies, Germany). The synthetic gene was cloned into a pET15b vector and transformed into competent One Shot\textsuperscript{™} BL21 Star\textsuperscript{™} (DE3) cells (Thermo Scientific). Recombinant protein expression was done in 3 L shake flasks containing 400 mL 2xyT media (100 µg/mL ampicillin). The bacterial culture was incubated at 37 °C for three hours (OD600 = 0.6) at which point cells were induced with 1 mM IPTG. The induced culture was then incubated for additional 16 h at 20 °C. Bacterial cells were harvested by centrifugation (10,000 × g) and the pellet was resuspended in 1× PBS (pH = 7.2) and lysed by sonication at 80% power with 5 pulsations for 2 × 5 min on ice. The cleared bacterial lysate was finally purified by ultracentrifugation (UC) using an Optiprep\textsuperscript{™} (Sigma) step (23, 29, and 35%) gradient. Specifically, 1.2 ml lysate was loaded on top of the density step-gradient and spun at 307,900 RCF (SW60Ti rotor, Beckmann Coulter) for 3.30 h at 16 °C. The UC sample was then divided into smaller fractions (~200 µL), which were analyzed for protein content by SDS-PAGE. Fractions containing SpyCatcher AP205 cVLPs were finally pooled and dialyzed against 20 mM Tris, 0.5 M NaCl buffer using a 1000 kDa MWCO SpectraPor Membrane.

**Vaccine production**

Purified, SpyTagged monomeric or oligomeric sE2 protein was mixed with SpyCatcher-AP205 cVLP at molar ratio 2:1 (antigen per cVLP binding site) and incubated for 36 h at 4 °C to generate sE2-cVLPs (Fig. 1B). Analysis of the vaccine mixture was done by SDS-PAGE. Briefly, 10 µL of the vaccine sample was mixed with 2 µL SDS loading dye (with or without Dithiothreitol). After heating the sample at 95 °C for 5 min, it was added (with a molecular size marker) to a NuPAGE Bis-Tris gel and run for 1 h at 170 V. The SDS-PAGE gel was finally stained with coomassie blue. SDS-PAGE densitometric analysis (ImageQuantTL) was used to determine the coupling efficiency of the SpyTag-SpyCatcher interaction by dividing the intensity of the cVLP band in the coupling lane with the intensity of the cVLP band in an input lane containing the equivalent amount of cVLP used in the coupling reaction and multiplying this value with 100. Excess unbound antigen was removed by repeating the ultracentrifugation step. sE2-cVLP containing fractions were pooled and dialyzed against 20 mM Tris, 0.5 M NaCl, pH7.9 as above and bacterial endotoxins were removed from the non-displayed and cVLP-displayed vaccines by a phase separation method using Triton X-114 detergent. Specifically, Triton X-114 was added in a 1:100 volume ratio to the protein sample, which had been chilled on ice. The sample was then mixed by vortexing and incubated on ice for 5 min. Subsequently, the sample was incubated at 37 °C for 5 min and centrifuged for 1 min at 16,000 × g at 37 °C. After separating the supernatant from the pellet, the above procedure was repeated using only the supernatant. Triton X-114 was finally removed by dialysis. All gel electrophoresis lanes shown in Coomassie stains of SDS-PAGE were run at the same time.

**Transmission electron microscopy (TEM)**

For TEM imaging, monomeric and oligomeric sE2-cVLP vaccines samples were diluted to 0.2 mg/mL in PBS and adsorbed to 200-mesh-carbon-coated grids, which were stained with 2% phosphotungstic acid (pH = 7.0) for 1 min. The negatively stained sample was finally analyzed in a CM100 BioTWIN electron microscope (Phillips) at an accelerating voltage of 80 kV. Pictures were taken using an Olympus Veleta camera.

**Dynamic Light Scattering (DLS)**

DLS was used to investigate the distribution of cVLP particle sizes. Samples were spun for 2.5 min at 16,000 RCF before analysis. Twenty repeated measurements were acquired for each sample (at 658 nm, 25 °C, WYATT Technology, DynaPro NanoStar). The
diameter was calculated from the hydrodynamic radius of the particles along with percent polydispersity (%Pd).

**Animal immunizations**

Mice were immunized with monomeric or oligomeric HCV sE2, alone or displayed on AP205 cVLP, to evaluate the immunogenicity and capacity for inducing NAbS of the different vaccines. Each immunization group contained six female BALB/c mice (8 weeks old) that were immunized intramuscularly in the thigh at weeks 1, 3, and 6. Mouse blood samples were taken at weeks 0 (pre-bleed), 6, and 9 (Fig. 2A). Per immunization, each mouse received 1.5 µg of either non-displayed or cVLP-displayed sE2 antigen formulated 1:1 (vol/vol) in Addavax (Invivogen).

**HCV sE2 specific serum IgG levels**

To determine the level of HCV sE2-specific antibody titers raised following immunization with both monomeric and oligomeric variants of the sE2 antigen displayed on cVLP or non-displayed, an enzyme-linked immunosorbent assay (ELISA) was used. Specifically, 96-well microtiter plates (Nunc MaxiSorp) were coated overnight at 4 °C with monomeric or oligomeric sE2 with C-terminal HIS-Tag (0.1 µg per well) produced in insect cells. PBS buffer +0.5% skim milk powder (w/v) was added for blocking of the plates. PBS was used for all washing steps. Secondary goat anti-mouse IgG Horseradish peroxidase (Novex) (1:2000 dilution) was used in as secondary antibody and 3,3',5,5'-Tetramethylbenzidine (TMB) as substrate for developing the plates. The colorimetric reaction was terminated with 0.2 M H₂SO₄ and the signal was measured at OD 450 nm. IgG titers were normalized across plates determined OD₅₀ (after modeling the serum dilution curves in Graphpad Prism (9.2.0) software using four parameter non-linear regression curve fitting).

**Competition ELISA against AR1B, AR2A and AR3A**

96-well microtiter plates (Nunc MaxiSorp) were coated with monomeric sE2 at 0.4 µg/ml ON at 4 °C. The following day, the plates were washed with PBS 0.1% Tween20 and blocked using PBS buffer with 1% skim milk powder (w/v) and 5% BSA (BSK). Three-fold dilution series of serum were made in PBS 0.1% Tween20 starting at 1:200 and incubated with the plates ON at 4 °C. The following day, human monoclonal antibodies AR1B, AR2A, and AR3A were used at 50% binding concentrations and with percent polydispersity (%Pd). Mouse blood samples were taken at weeks 0 (pre-bleed), 6, and 9 (Fig. 2A). Per immunization, each mouse received 1.5 µg of either non-displayed or cVLP-displayed sE2 antigen formulated 1:1 (vol/vol) in Addavax (Invivogen).

**Antigenic sE2-cVLP characterization by ELISA**

96-well microtiter plates (Nunc MaxiSorp) were coated with cVLPs displaying monomeric or oligomeric sE2 (0.1 µg per well). Dilution series of HCV E2-specific human monoclonal antibodies AR1B, AR2A, or AR3A²⁴ were subsequently tested for binding to the immobilized E2-cVLP complexes to probe epitope accessibility. PBS buffer +0.5% skim milk powder (w/v) was used for blocking the plates and for serum dilutions. PBS was used for all washing steps. Secondary goat anti-human IgG Horseradish peroxidase (Agilent Technologies) was used as secondary antibody (1:5000 dilution) and TMB as substrate for developing the plates. The colorimetric reaction was terminated with 0.2 M H₂SO₄ and the signal was measured at OD 450 nm.

**In vitro HCV neutralization assay**

7 × 10³ of HCV permissive Huh7.5 cells were plated per well in poly-D-lysine 96-well plates and incubated for 24 h. All neutralization assays were done with purified IgG instead of full serum to avoid non-IgG effects from mouse serum components. The following day, a dilution series of mouse-derived antibodies (at the highest dose of 0.5–1 mg/ml) was made using DMEM (Gibco) supplemented with 10% fetal calf serum (Sigma) and penicillin/streptomycin (Sigma) (full medium). This was incubated in a total volume of 10 µl with cell-culture infectious JFH1-based Core-NS2 recombinant HCVcc stocks, referred to by the isolate name of the envelope proteins: H77 (genotype 1a), TN (genotype 1a), J4 (genotype 1b), J6 (genotype 2a), T9 (genotype 2a), DBN (genotype 3a), ED43 (genotype 4a), SA13 (genotype 5a) and HK6a (genotype 6a) in different passages corresponding to a final read-out of 50–200 FFU per well. The virus/antibody mixes were, along with eight replicates of virus only, incubated for 1.5 h at 37 °C before addition of an additional 20 µl of full medium and incubation with Huh7.5 cells for 2.5 h at 37 °C in 5% CO₂. Cells were washed, and fresh medium was added prior to incubation for a total infection time of 48 h before fixation. Following fixation, the cells were incubated with anti-mouse Fab fragments (Jackson Immuno Research) to block the Fc region of the mouse antibodies.

Cells were stained by overnight incubation with N56-specific antibody 9E10 in PBS buffer with BSK. Cells were washed three times in PBS buffer with 0.1%Tween20 and incubated 1 h at room temperature with secondary antibody Anti-mouse IgG, Horseradish Peroxidase (Amersham Biosciences) at a dilution of 1:2000 and visualized by DAB staining (VWR). FFUs were counted on an ImmunoSpot series 5 UV analyzer (CTL Europe GmbH) with customized software. The mean FFU count of 8 negative-control wells was subtracted from FFU counts in experimental wells. The data were normalized to 8 replicates of virus only and analyzed using three or four parameters curve fitting in GraphPad Prism 9.2.0, bottom set to 0, top set to 100.

**Statistical analysis**

All statistical analysis and graphs were prepared using the GraphPad Prism 9.2.0 software. The non-parametric, two tailed, Mann–Whitney Rank Sum Test unpaired comparison between immunization groups was used to test for statistical difference amongst different vaccination groups; statistical significance was defined as p < 0.05.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.
REFERENCES

1. Bukh, J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemiologic control. J. Hepatol. 65, 52–521 (2016).

2. World Health Organization. Hepatitis C. Fact sheet. WHO website (online) (2020). https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.

3. Thomas, D. L. Global elimination of chronic hepatitis. N. Engl. J. Med. 380, 2041–2050 (2019).

4. World Health Organization. Welcome to 2020—the decade for disease elimination (2020). https://www.who.int/news-room/feature-stories/detail/welcome-to-2020-the-decade-for-disease-elimination.

5. Bartenschlager, R. et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res. 248, 53–62 (2018).

6. Feld, J. J. & Ward, J. W. Key elements on the pathway to HCV elimination: Lessons learned from the AASLD HCV Special Interest Group 2020. Hepatol. Commun. 5, 911–922 (2021).

7. Bukh, J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39, 1469–1475 (2004).

8. Liang, T. J. Current progress in development of hepatitis C virus vaccines. Nat. Med. 19, 869–878 (2013).

9. Fauvelle, C. et al. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert. Rev. Vaccines 15, 1535–1544 (2016).

10. Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6, 261ra153 (2014).

11. Page, K. et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N. Engl. J. Med. 384, 541–549 (2021).

12. Pestka, J. M. et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104, 6025–6030 (2007).

13. Osburn, W. O. et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 59, 2140–2151 (2014).

14. Kinchen, V. J. et al. Plasma deconvolution identifies functional homodimer that effectively neutralizes hepatitis C virus genotype 5a: Failure of homologous neutralizing-antibody treatment to control infection. J. Virol. 95, e0167521 (2022).

15. Correia, J. M. et al. Development and characterization of hepatitis C virus genotype 1b vaccines. Vaccine 37, 935–941 (2019).

16. Claxton, H. E. et al. Development of a vaccine for hepatitis C virus. Expert. Rev. Vaccines 13, 51–61 (2014).

17. Augestad, E. H. et al. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. Sci. Adv. 6, eabb5336 (2020).

18. von Hahn, L. et al. Engineering of HCV vaccines for humoral immunity. J. Virol. 86, 2573–2582 (2012).

19. Forst, X. et al. Antigenic and immunogenic evaluation of permutations of hepatitis C virus E2 glycoprotein in a large multicenter clinical trial. Proc. Natl Acad. Sci. USA 116, 10039–10047 (2019).

20. Jiao, X. S. et al. Development of a vaccine for hepatitis C virus genotype 5a: Failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 198, 1756–1765 (2008).

21. Scheel, T. K. et al. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS5B by using previously identified mutations. J. Virol. 85, 2891–2906 (2011).

22. Prentoe, J. et al. An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that efficiently blocks virus entry. J. Virol. 91, e01668-16 (2017).

23. Wang, X. et al. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut 68, 140–149 (2019).

24. Khera, T. et al. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. J. Hepatol. 70, 593–602 (2019).

25. Vlieheer, P. T. et al. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology 65, 1117–1131 (2017).

26. He, L. et al. Proof of concept for rational design of hepatitis C virus E2 core nanoparticles vaccines. Sci. Adv. 6, eaaas2225 (2020).

27. Page, K. et al. Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization. J. Virol. 94, e00704-20 (2020).

28. He, L. et al. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat. Commun. 7, 1–15 (2016).

29.崇高, J. M. et al. Virus-like particles containing the E2 core domain of hepatitis C virus generate broadly neutralizing antibodies in guinea pigs. J. Virol. 96, e0167521 (2022).

30. Bachmann, M. F. et al. The influence of antigen organization on B cell responiveness. Science 262, 1448–1451 (1993).

31. Li, D. et al. Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice. J. Virol. 90, 10486–10498 (2016).

32. Thorne, S. et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. Nanobiotechnol. 14, 30 (2016).

33. Petska, J. M. et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nat. Commun. 12, 324 (2021).

34. Gottwein, J. M. et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CDB1 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49, 364–377 (2009).

35. Velazquez-Moctezuma, R., Law, M., Bukh, J. & Prentoe, J. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody ARSA. PLoS Pathog. 13, e1006214 (2017).

36. Bankowicz, D. et al. Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralizing antibodies. Gut 70, 1734–1745 (2021).

37. Center, R. J. et al. Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine. J. Biol. Chem. 295, 7179–7192 (2020).

38. Salas, J. H. et al. An antigenically diverse, representative panel of envelope glycoproteins for hepatitis C virus vaccine development. Gastroenterology 162, 562–574 (2022).

39. Owsiakia, A., Clayton, R. F., Loomis-Price, L. D., McKeating, J. A. & Patel, A. H. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82, 1477–1483 (2001).

40. Augestad, E. H., Bukh, J. & Prentoe, J. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1. Curr. Opin. Virol. 50, 69–75 (2021).

41. Augestad, E. H. et al. Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. Sci. Adv. 6, eabb5938 (2020).

42. Olesen, C. H., Augestad, E. H., Troise, F., Bukh, J. & Prentoe, J. In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus. PLoS Pathog. 17, e1009720 (2021).

43. Prentoe, J. et al. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. Proc. Natl Acad. Sci. USA 116, 10039–10047 (2019).

44. Prentoe, J. et al. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS One 16, e0255336 (2021).

45. Forns, X., Allander, T., Rohwer-Nutter, P. & Bukh, J. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. Virology 274, 75–85 (2000).

46. Scheel, T. K. et al. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl Acad. Sci. USA 105, 997–1002 (2008).

47. Jensen, T. B. et al. Highly efficient JFH1-based cell culture system for hepatitis C virus genotype 5a: Failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 198, 1756–1765 (2008).

48. Scheel, T. K. et al. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS5B by using previously identified mutations. J. Virol. 85, 2891–2906 (2011).
ACKNOWLEDGEMENTS
The authors would like to thank Lotte Mikkelsen and Anne-Louise Sørensen (Copenhagen University Hospital, Hvidovre) and Anne Corfitz and Nahla Chehabi (Center for Medical Parasitology, UCPH) for technical assistance, Bjarne Ørskov Lindhardt (Copenhagen University Hospital, Hvidovre), and Carsten Geisler and Charlotte Menné Bonefeld (University of Copenhagen) for their support of the project and Mansun Law (Scripps Research Institute, US) and Charles Rice (Rockefeller University, US) for providing reagents. Furthermore, we would like to thank the Core Facility for Integrated Microscopy, Faculty of Health and Medical Sciences, University of Copenhagen for their support with the Transmission Electron Microscopy images, as well as the Biophysics Facility—Protein Structure and Function Program from Center for Protein Research, Copenhagen, for aiding with DLS measurements. This study was supported by funding from the Danish Cancer Society (R204-A12639 Project Grant to J.B.), the Lundbeck Foundation (R303-2018-3396 Postdoc grant to R.V.-M. and R335-2019-2052 Fellowship grant to J.P.), the Independent Research Fund Denmark (4004-00598 Advanced Grant to J.B. and 6110-00177B Project Grant to T.T., M.A.N., and A.F.S.), the Novo Nordisk Foundation NNF17OC0029372 Project Grant and NNF19OC0054518 Distinguished Investigator Grant both to J.B.) and by Eurostars, funded by the European commission and Innovation fund Denmark (E11019 to T.T., M.A.N., and A.F.S.).

AUTHOR CONTRIBUTIONS
J.P. and C.M.J. contributed equally to the study. J.P., C.M.J., J.B., and A.F.S. conceived and designed the experiments. J.P., C.M.J., R.V.-M., A.S., V.S., and S.T. performed experiments. J.P. and C.M.J. wrote the paper. J.P., C.M.J., R.V.-M., A.S., T.J., T.T., M.A.N., A.S., J.B., and A.F.S. contributed to analyzing and discussing the included data. J.P., C.M.J., R.V.-M., A.S., T.J., S.C., V.S., S.T., T.T., M.A.N., A.S., J.B., and A.F.S. Authors contributed to revising and proof-reading as well as accepting the final manuscript.

COMPETING INTERESTS
C.M.J., S.T., T.T., M.A.N., A.S., and A.F.S. are co-inventors on a patent application on the used AP205 cVLP vaccine technology (WO2016112921 A1) licensed to AdaptVac. A.F.S. is currently partially employed by AdaptVac. The rest of the authors declare no competing interests.

ETHICAL
All mouse studies included in this paper were planned and conducted according to the Federation of European Laboratory Animal Science Associations (FELASA) Guidelines and were approved by the Danish Animal Experiments Inspectorate (Approval number: 2013-15-2934-00902/BES).

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41541-022-00570-1.

Correspondence and requests for materials should be addressed to Jannick Prentoe.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022